MX2022016049A - Aptameros para aplicaciones para el cuidado personal de la salud. - Google Patents

Aptameros para aplicaciones para el cuidado personal de la salud.

Info

Publication number
MX2022016049A
MX2022016049A MX2022016049A MX2022016049A MX2022016049A MX 2022016049 A MX2022016049 A MX 2022016049A MX 2022016049 A MX2022016049 A MX 2022016049A MX 2022016049 A MX2022016049 A MX 2022016049A MX 2022016049 A MX2022016049 A MX 2022016049A
Authority
MX
Mexico
Prior art keywords
icam
aptamers
adhesion molecule
health care
intercellular adhesion
Prior art date
Application number
MX2022016049A
Other languages
English (en)
Inventor
Kelly Lee Schmeichel
Adam Michael Pitz
Juan Esteban Velasquez
Erin Nicole Swigart
Amy Violet Trejo
Gregory Allen Penner
Spencer Christopher Rupard
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MX2022016049A publication Critical patent/MX2022016049A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composición de aptámeros que tiene uno o más oligonucleótidos que incluyen al menos uno de desoxirribonucleótidos, ribonucleótidos, derivados de desoxirribonucleótidos, derivados de ribonucleótidos, o mezclas de estos. La composición de aptámeros tiene una afinidad de unión por una o más glicoproteínas de membrana celular seleccionadas del grupo que consiste en: molécula de adhesión intercelular 1 (ICAM-1), miembros de la familia del receptor de lipoproteínas de baja densidad (LDLR), y miembro de la familia relacionada a cadherina 3 (CDHR3), preferentemente molécula de adhesión intercelular 1 (ICAM-1), y se configura para reducir la unión de uno o más rinovirus humanos a la molécula de adhesión intercelular 1 (ICAM-1).
MX2022016049A 2020-06-25 2021-06-24 Aptameros para aplicaciones para el cuidado personal de la salud. MX2022016049A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043952P 2020-06-25 2020-06-25
PCT/US2021/038785 WO2021262911A1 (en) 2020-06-25 2021-06-24 Aptamers for personal health care applications

Publications (1)

Publication Number Publication Date
MX2022016049A true MX2022016049A (es) 2023-02-09

Family

ID=76943162

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016049A MX2022016049A (es) 2020-06-25 2021-06-24 Aptameros para aplicaciones para el cuidado personal de la salud.

Country Status (8)

Country Link
US (1) US11859187B2 (es)
EP (1) EP4172337A1 (es)
CN (1) CN115996729A (es)
AU (1) AU2021296450A1 (es)
BR (1) BR112022025763A2 (es)
CA (1) CA3176605A1 (es)
MX (1) MX2022016049A (es)
WO (1) WO2021262911A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230340495A1 (en) * 2021-12-14 2023-10-26 The Procter & Gamble Company Aptamers for personal health care applications

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2763958B2 (ja) 1990-06-11 1998-06-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンド
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
JP2007532662A (ja) 2004-04-13 2007-11-15 （オーエスアイ）アイテツク・インコーポレーテツド 高分子量の立体的な基へ抱合された核酸アプタマー
US8778307B2 (en) 2009-06-05 2014-07-15 University Of Maryland, College Park Targeted carriers for drug delivery across the gastrointestinal epithelium
EP2437727A4 (en) 2009-06-05 2013-12-25 Univ Maryland PEPTIDES FOR THE TRANSPORT OF THERAPEUTICS AND THEIR CARRIER IN MICE MODELS AND WITH HUMANS
WO2010144295A1 (en) 2009-06-09 2010-12-16 University Of Miami Aptamer-targeted costimulatory ligand aptamer
BR112015009138A2 (pt) 2012-10-23 2020-10-20 Caris Life Sciences Switzerland Holdings, S.A.R.L. métodos para caracterizar um câncer
JP2016533752A (ja) 2013-08-28 2016-11-04 カリス ライフ サイエンシズ スウィッツァーランド ホー オリゴヌクレオチドプローブおよびその使用
DK3344805T3 (da) 2015-09-04 2022-03-07 Neoventures Biotechnology Inc Fremgangsmåde til udvælgelse af aptamerer til ubundne mål
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
WO2020020947A1 (en) 2018-07-26 2020-01-30 Bracco Imaging Spa Icam-1 aptamers, diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
US20210403919A1 (en) 2021-12-30
US11859187B2 (en) 2024-01-02
CN115996729A (zh) 2023-04-21
WO2021262911A1 (en) 2021-12-30
EP4172337A1 (en) 2023-05-03
AU2021296450A1 (en) 2022-10-20
CA3176605A1 (en) 2021-12-30
BR112022025763A2 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
Pant et al. Spicy seizure
ATE489088T1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid- derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
UY28760A1 (es) Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
MX2022016049A (es) Aptameros para aplicaciones para el cuidado personal de la salud.
GEP20125565B (en) Lactam compounds and their pharmaceutical use
BRPI0518011A (pt) uso de tetraidrocanabidivarina, métodos para o tratamento de uma doença ou condição e para cosmeticamente beneficiar a perda de peso, e, uso de um antagonista do receptor de canabinóide neutro
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
MA32534B1 (fr) Dérivés de cyclohexylamide et leur utilisation en tant qu'antagonistes des récepteurs de crf-1
DK1638551T3 (da) Immunosuppressive forbindelser og sammensætninger
DE602006020273D1 (de) Substituierte heteroarylamidmodulatoren der aktivität des glucokortikoidrezeptors, von ap-1 und/oder von nfkb und anwendung davon
MA28673B1 (fr) Derives de pyrazole, compositions contenant lesdits composes et methodes d'utilisation
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
MX2007004936A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1.
ECSP088852A (es) Azolopirimidinas como inhibidores de la actividad canabinoidea 1
ATE433966T1 (de) Methylendipiperidinderivate
GB2460597A (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
TR201004346T2 (tr) Depresyon ve anksiyetenin tedavisinde farmasötikal kompozisyonlar.
MX2021005984A (es) Bacterias christensenellaceae que incluyen christensenella minuta y usos de las mismas.
PT1853232E (pt) Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização
MX2020009810A (es) Nuevo uso de las composiciones microbiológicas.
CY1110733T1 (el) Κυκλικα παραγωγα ως ρυθμιστες της δραστικοτητας υποδοχεα χημειοκινων
Wedel et al. SAFit2 reduces neuroinflammation and ameliorates nerve injury-induced neuropathic pain
Lee et al. Effects of obovatol on GSH depleted glia-mediated neurotoxicity and oxidative damage
Marmolejo-Garza et al. Negative modulation of mitochondrial calcium uniporter complex protects neurons against ferroptosis